GlassScriptPhysician profile
Nicholas J Thames
NPI 1457029951
$3,831.75
in general payments reported to CMS, 2019-2025
18 companies · $943 in 2025
The $943 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,052 · 2024: $1,836 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769 · Education: $63.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.70 |
| Education | $63.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $787.20 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $743.71 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $496.52 | 2023-2025 | Caplyta |
| Indivior INC. | $296.11 | 2023-2025 | Sublocade, Perseris |
| Alkermes, INC. | $206.34 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $192.13 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $191.22 | 2023-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $164.97 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $154.74 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $131.83 | 2024-2025 | Auvelity |
| Lundbeck LLC | $117.00 | 2023-2024 | Rexulti |
| Braeburn INC. | $79.15 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $78.82 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $78.54 | 2023-2024 | Trintellix |
| Tempus Ai, INC | $50.42 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $23.26 | 2024 | Azstarys |
| Uswm, LLC | $21.28 | 2024 | Lucemyra |
| Sage Therapeutics, LLC | $18.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Thames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.